Evidence map›Paper›PMID 40650859›Full record

ArticleOncology and therapy2025

Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer.

Kalé Kponee-Shovein, Vimalanand S Prabhu, Yan Song, Lei Chen, Mu Cheng, Yeran Li, Yezhou Sun, Annalise Hilts, Qi Hua, Jasmine Lichfield and 1 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Kalé Kponee-ShoveinAnalysis Group, Inc., 111 Huntington Avenue 14th Floor, Boston, MA, 02199, USA. Kale.Kponee-Shovein@analysisgroup.com.
Vimalanand S PrabhuMerck & Co., Inc., Rahway, NJ, USA.
Yan SongAnalysis Group, Inc., 111 Huntington Avenue 14th Floor, Boston, MA, 02199, USA.
Lei ChenMerck & Co., Inc., Rahway, NJ, USA.
Mu ChengAnalysis Group, Inc., 111 Huntington Avenue 14th Floor, Boston, MA, 02199, USA.
Yeran LiMerck & Co., Inc., Rahway, NJ, USA.
Yezhou SunMerck & Co., Inc., Rahway, NJ, USA.
Annalise HiltsAnalysis Group, Inc., 111 Huntington Avenue 14th Floor, Boston, MA, 02199, USA.
Qi HuaAnalysis Group, Inc., 111 Huntington Avenue 14th Floor, Boston, MA, 02199, USA.
Jasmine LichfieldMSD (UK) Limited, London, UK.
Linda DuskaUniversity of Virginia, Charlottesville, VA, USA.

Funding

NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032I
6 · The paper itself

Abstract

introductionDisease-free survival (DFS) is commonly a primary endpoint in clinical trials of investigational therapies for early stage and/or high-risk endometrial cancer and may be indicative of therapeutic benefit prior to maturity of overall survival (OS) data; however, its role as a predictor of OS in high-risk endometrial cancer is unknown. Therefore, this study estimates the individual-level correlation between DFS and OS and the association between recurrent disease and OS in patients with high-risk endometrial cancer receiving adjuvant chemotherapy.

methodsMedicare beneficiaries with high-risk endometrial cancer who underwent surgery followed by adjuvant chemotherapy were identified from Surveillance, Epidemiology, and End Results data (2007-2019). OS and DFS from adjuvant chemotherapy initiation were estimated by Kaplan-Meier (KM) analyses; correlation was evaluated using Kendall's τ rank correlation. Multivariable Cox models were used to compare OS between recurrent and nonrecurrent patients at three landmark points and over the follow-up period.

resultsAmong 771 patients, 250 (32.4%) experienced recurrence (median follow-up 3.6 years). Median OS was not reached (5-year OS 72.7%); median DFS was 7.9 years (5-year DFS 58.1%). A positive correlation between DFS and OS was observed [Kendall's τ = 0.83; 95% confidence interval (CI) 0.79‒0.86; p < 0.001]. Across landmark points, recurrent patients had 3.8-5.2-fold higher risk of mortality (all p < 0.001). During follow-up, patients with recurrence had a higher risk of mortality than those without (hazard ratio 7.9; 95% CI 5.7‒10.8; p < 0.001).

conclusionsThe findings of this study suggest that DFS may be a useful surrogate for OS in high-risk endometrial cancer, though validation in trial-level meta-analyses is needed, and highlight the substantial burden associated with recurrent disease, as evidenced by the four-fold to eight-fold higher risk of mortality across comparative assessments of OS. Effective novel therapies are needed to reduce the considerable burden of disease recurrence in this population.

Indexed as

Adjuvant chemotherapyDisease burdenDisease-free survivalDisease recurrenceHigh-risk endometrial cancerOverall survival

Identifiers

PMID40650859
PMCPMC12647473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.